SkinBioTherapeutics PLC
LSE:SBTX

Watchlist Manager
SkinBioTherapeutics PLC Logo
SkinBioTherapeutics PLC
LSE:SBTX
Watchlist
Price: 12.25 GBX -2.97%
Market Cap: 31.7m GBX

Relative Value

The Relative Value of one SBTX stock under the Base Case scenario is 22.76 GBX. Compared to the current market price of 12.25 GBX, SkinBioTherapeutics PLC is Undervalued by 46%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SBTX Relative Value
Base Case
22.76 GBX
Undervaluation 46%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
22
Median 3Y
148.1
Median 5Y
34.3
Industry
7.9
Forward
6.8
vs History
vs Industry
Median 3Y
-15.3
Median 5Y
-18.8
Industry
24
Forward
-17.9
vs History
vs Industry
Median 3Y
-18
Median 5Y
-21.3
Industry
21.6
vs History
vs Industry
Median 3Y
-21.1
Median 5Y
-29.2
Industry
23.7
vs History
95
vs Industry
4
Median 3Y
11.6
Median 5Y
16.7
Industry
3.4
vs History
76
vs Industry
18
Median 3Y
130.9
Median 5Y
33.6
Industry
8.3
Forward
6.8
vs History
76
vs Industry
11
Median 3Y
208
Median 5Y
59.5
Industry
10.3
vs History
vs Industry
Median 3Y
-16.1
Median 5Y
-18.8
Industry
6.7
Forward
-103.8
vs History
vs Industry
Median 3Y
-14.6
Median 5Y
-18.1
Industry
7.2
Forward
-28.3
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-20.7
Industry
8.2
vs History
vs Industry
Median 3Y
-17.1
Median 5Y
-19.6
Industry
6.7
vs History
96
vs Industry
16
Median 3Y
23.3
Median 5Y
59.4
Industry
5.7

Multiples Across Competitors

SBTX Competitors Multiples
SkinBioTherapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
SkinBioTherapeutics PLC
LSE:SBTX
31.7m GBP 11.8 -12.3 -13.9 -12.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -196 873.6 -194 627
US
Abbvie Inc
NYSE:ABBV
394.1B USD 6.6 167.8 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
168.9B USD 4.7 24.1 17.5 17.5
US
Gilead Sciences Inc
NASDAQ:GILD
148.2B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111B USD 9.5 30.2 22.1 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -573.9 -558.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.9B USD 5.1 15.9 15.1 17.1
AU
CSL Ltd
ASX:CSL
87.9B AUD 3.7 19.5 13.1 16.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.7B USD 17 1 256.1 165.2 200.4
NL
argenx SE
XBRU:ARGX
46.9B EUR 15.2 35.6 61.7 63.2
P/E Multiple
Earnings Growth PEG
UK
SkinBioTherapeutics PLC
LSE:SBTX
Average P/E: 195.9
Negative Multiple: -12.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
9%
1.8
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 256.1
N/A N/A
NL
argenx SE
XBRU:ARGX
35.6
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
SkinBioTherapeutics PLC
LSE:SBTX
Average EV/EBITDA: 40.4
Negative Multiple: -13.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.5
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.2
N/A N/A
NL
argenx SE
XBRU:ARGX
61.7
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
SkinBioTherapeutics PLC
LSE:SBTX
Average EV/EBIT: 46.6
Negative Multiple: -12.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 627 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.5
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
13%
1.3
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
200.4
N/A N/A
NL
argenx SE
XBRU:ARGX
63.2
N/A N/A